Shire PLC (SHP) Earns Hold Rating from Liberum Capital
Shire PLC (LON:SHP)‘s stock had its “hold” rating reissued by research analysts at Liberum Capital in a report released on Tuesday. They currently have a GBX 4,200 ($55.24) price target on the biopharmaceutical company’s stock. Liberum Capital’s price objective points to a potential upside of 20.03% from the company’s previous close.
A number of other equities analysts have also recently issued reports on the company. Shore Capital reissued a “buy” rating on shares of Shire PLC in a report on Wednesday, July 19th. J P Morgan Chase & Co reissued an “overweight” rating on shares of Shire PLC in a report on Thursday, July 20th. Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,350 ($70.37) target price on shares of Shire PLC in a report on Friday, August 4th. Beaufort Securities reissued a “long term buy” rating and issued a GBX 4,900 ($64.45) target price (down from GBX 6,200 ($81.55)) on shares of Shire PLC in a report on Friday, August 4th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a GBX 6,000 ($78.92) target price on shares of Shire PLC in a report on Friday, August 4th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 5,358.82 ($70.48).
Shares of Shire PLC (LON:SHP) opened at GBX 3,499 ($46.02) on Tuesday. Shire PLC has a 52-week low of GBX 3,435.50 ($45.19) and a 52-week high of GBX 5,107 ($67.17).
In related news, insider Flemming Ornskov purchased 8,400 shares of Shire PLC stock in a transaction dated Tuesday, August 22nd. The shares were acquired at an average cost of GBX 3,665 ($48.20) per share, for a total transaction of £307,860 ($404,919.11). Also, insider Anne Minto purchased 190 shares of Shire PLC stock in a transaction dated Friday, September 29th. The stock was bought at an average price of GBX 3,785 ($49.78) per share, for a total transaction of £7,191.50 ($9,458.77).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.